New daily pill shows promise in controlling leukemia

NCT ID NCT04008706

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a daily medication called acalabrutinib in 552 adults with chronic lymphocytic leukemia (CLL), a type of blood cancer. Participants included those newly diagnosed, those whose cancer returned, and those who had previously taken a similar drug. The goal was to see if the drug is safe and helps control the cancer, but patients must keep taking it long-term to manage the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Show contact details

Locations

Research Site

Chandler, Arizona, 85224, United States
Research Site

Long Beach, California, 90806, United States
Research Site

Redlands, California, 92373, United States
Research Site

Whittier, California, 90603, United States
Research Site

Fort Myers, Florida, 33908, United States
Research Site

Jacksonville, Florida, 32256, United States
Research Site

St. Petersburg, Florida, 33705, United States
Research Site

Marietta, Georgia, 30060, United States
Research Site

Normal, Illinois, 61761, United States
Research Site

Peoria, Illinois, 61615, United States
Research Site

Fort Wayne, Indiana, 46845, United States
Research Site

Indianapolis, Indiana, 46260, United States
Research Site

Shreveport, Louisiana, 71105, United States
Research Site

Saint Cloud, Minnesota, 56303, United States
Research Site

Kansas City, Missouri, 64132, United States
Research Site

Bethlehem, Pennsylvania, 18015, United States
Research Site

Chattanooga, Tennessee, 37404, United States
Research Site

Nashville, Tennessee, 37203, United States
Research Site

Dallas, Texas, 75235, United States
Research Site

Adelaide, 5000, Australia
Research Site

Bedford Park, 5042, Australia
Research Site

Clayton, 3168, Australia
Research Site

Fitzroy, 3065, Australia
Research Site

Nedlands, 6009, Australia
Research Site

South Brisbane, 4101, Australia
Research Site

Belo Horizonte, 30130-100, Brazil
Research Site

Curitiba, 81520-060, Brazil
Research Site

Goiânia, 74605-020, Brazil
Research Site

Porto Alegre, 90035-003, Brazil
Research Site

Porto Alegre, 90110-270, Brazil
Research Site

Ribeirão Preto, 14048-900, Brazil
Research Site

São Paulo, 01236-030, Brazil
Research Site

São Paulo, 01323-900, Brazil
Research Site

Calgary, Alberta, T2N 4N2, Canada
Research Site

Edmonton, Alberta, T6G 1Z2, Canada
Research Site

Victoria, British Columbia, V8R 6V5, Canada
Research Site

Winnipeg, Manitoba, R3E 0V9, Canada
Research Site

Halifax, Nova Scotia, B3H 1V7, Canada
Research Site

Brampton, Ontario, L6R 3J7, Canada
Research Site

Newmarket, Ontario, L3Y 2P9, Canada
Research Site

Ottawa, Ontario, K1H 8L6, Canada
Research Site

Aalborg, 9100, Denmark
Research Site

Aarhus, 8200, Denmark
Research Site

Herlev, 2730, Denmark
Research Site

København Ø, 2100, Denmark
Research Site

Odense, 5000, Denmark
Research Site

Roskilde, 4000, Denmark
Research Site

Hus, 00029, Finland
Research Site

Kuopio, 70210, Finland
Research Site

Tampere, 33521, Finland
Research Site

Bordeaux, 33076, France
Research Site

Brest, 29609, France
Research Site

Limoges, 87042, France
Research Site

Reims, 51092, France
Research Site

Tours, 37000, France
Research Site

Vandœuvre-lès-Nancy, 54511, France
Research Site

Bayern, 63739, Germany
Research Site

Essen, 45147, Germany
Research Site

Homburg, 66421, Germany
Research Site

Porta Westfalica, 32457, Germany
Research Site

Schwäbisch Hall, 74523, Germany
Research Site

Catanzaro, 88100, Italy
Research Site

Milan, 20122, Italy
Research Site

Roma, 00161, Italy
Research Site

Roma, 00168, Italy
Research Site

Siena, 53100, Italy
Research Site

Arnhem, 6815 AD, Netherlands
Research Site

Dordrecht, 3318 AT, Netherlands
Research Site

Utrecht, 3584 CX, Netherlands
Research Site

Bergen, 5053, Norway
Research Site

Oslo, 1478, Norway
Research Site

Trondheim, 7006, Norway
Research Site

Moscow, 115478, Russia
Research Site

Moscow, 125167, Russia
Research Site

Moscow, 125284, Russia
Research Site

Nizhny Novgorod, 603126, Russia
Research Site

Petrozavodsk, 185019, Russia
Research Site

Saint Petersburg, 191024, Russia
Research Site

Saint Petersburg, 194291, Russia
Research Site

Saint Petersburg, 197022, Russia
Research Site

Saint Petersburg, 197110, Russia
Research Site

Saint Petersburg, 197341, Russia
Research Site

Smolensk, 214015, Russia
Research Site

Smolensk, 214031, Russia
Research Site

Syktyvkar, 167904, Russia
Research Site

Busan, 49241, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 06591, South Korea
Research Site

Seoul, 135-710, South Korea
Research Site

Ulsan, 44033, South Korea
Research Site

Barcelona, 08036, Spain
Research Site

Madrid, 28006, Spain
Research Site

Madrid, 28041, Spain
Research Site

Marbella, 29603, Spain
Research Site

Ourense, 32005, Spain
Research Site

Oviedo, 33011, Spain
Research Site

Vitoria-Gasteiz, 01009, Spain
Research Site

Zaragoza, 50009, Spain
Research Site

Luleå, 97180, Sweden
Research Site

Lund, 221 85, Sweden
Research Site

Uppsala, 75185, Sweden
Research Site

Taichung, 40705, Taiwan
Research Site

Tainan, 704, Taiwan
Research Site

Taipei, 10002, Taiwan
Research Site

Taipei, 11217, Taiwan
Research Site

Liverpool, L7 8XP, United Kingdom
Research Site

Newmarket, CB8 7XN, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.